Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide in Steroid-Refractory Gastrointestinal Acute Graft Versus Host Disease
2023-507960-38-00Phase 2Completed
- Sponsor
- VectivBio
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of apraglutide in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by VectivBio. Primary endpoints: Adverse events (AEs; System Organ Class, frequency and severity), Adverse events of special interest related to apraglutide and 4 more. Started May 2024; status: completed.
02
Drugs
apraglutide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2023-507960-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507960-38-00.